Global Critical Care Therapeutics Market 2017-2021

Thursday, March 9, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, March 8, 2017 /PRNewswire/ -- Critical Care Therapeutics

Critical care or intensive care is the close

monitoring and treatment given to individuals with acute, life-threatening illness or injuries such as shock, burns, accidents, complicated surgeries, sepsis, and severe breathing problems. It usually takes place in an ICU or trauma center. Plasma is
the fluid portion of the blood, in which all the blood cells are suspended. It makes up about 55% of the total volume of the blood. The other components such as red blood cell (RBC), white blood cell (WBC), and platelets together comprise the remaining 45% of the blood. Plasma is mainly made up of water, which accounts for about 91% of the total volume. Technavio's analysts forecast the global critical care therapeutics market to grow at a CAGR of 3.62% during the period 2017-2021. Covered in this report The report covers the present scenario and the growth prospects of the global critical care therapeutics market for 2017-2021. To calculate the market size, the report considers the revenue generated from sales of critical care therapeutics was considered. The market is divided into the following segments based on geography: - Americas - APAC - EMEA Technavio's report, Global Critical Care Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendorsoperating in this market. Key vendors - CSL Behring - Grifols - Kedrion Biopharma - Octapharma - Shire Other prominent vendors - Abeona Therapeutics - ADMA Biologics - Albumedix - Armetheon - Asklepios BioPharmaceutical - Aspen Pharma - Baxter - Bayer HealthCare - Bio Products Laboratory - BioDelivery Sciences - Biogen Idec - BioMarin - Biotest Pharmaceuticals - Bristol-Myers Squibb - Catalyst Biosciences - China Biologic Products - Cosmo Pharmaceuticals - Kamada - King Pharmaceuticals - Medxbio - Merck - Mitsubishi Tanabe Pharma - Novo Nordisk - Novozymes - Portola Pharmaceuticals - ProMetic Life Sciences - rEVO Biologics - Rockwell Medical - Sanquin - Shanghai RAAS - Teva Pharmaceutical - The Medicines Company - Thermo Fisher Scientific - Tianjin SinoBiotech & Beijing Bio-Fortune - Ventria Bioscience Market driver - Growing preference for marketed products over alternative treatment options. - For a full, detailed list, view our report Market challenge - Existence of plasma fractionation supply and demand gap. - For a full, detailed list, view our report Market trend - Increased development of recombinant products for critical care use. - For a full, detailed list, view our report Key questions answered in this report - What will the market size be in 2021 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the Key vendorsin this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report. Read the full report: methodology is based on extensive primary and secondary research. Primary research includes in-depth interviews with industry experts, vendors, resellers and customers. Secondary research includes Technavio Platform, industry publications, company reports, news articles, analyst reports, trade associations and the data published by Government agencies.Read the full report: Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________Contact Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

To view the original version on PR Newswire, visit:

SOURCE Reportlinker

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store